News Sentiment

NRSN sentiment intelligence

Neurosense Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.68 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.1% over one week, -15.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.1% Price reacting lower
Trend fit Trend inactive -15.0% over four weeks
Fair value -36.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 40
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 9
PR Newswire 8
Market source 6
TradingKey 6
dars.gov.et 3
MT Newswires 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 18
Analyst action 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Stock Titan Direct company coverage

NeuroSense joins ALS expert webinar on PrimeC and Phase 3 plans

NeuroSense Therapeutics (NRSN) will participate in a Roth Capital Partners webinar on July 8, 2026, focusing on ALS treatment, clinical trial endpoints, and its drug candidate, PrimeC. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon Ben-Noon,

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 07:10
Source
Stock Titan
PR Newswire Direct company coverage

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Therapeutics will participate in a Roth Capital Partners-hosted KOL webinar titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)" on Wednesday, July 8, 2026, at 11:00 a.m. ET. The webinar will feature ALS expert Professor Jeremy Shefner and NeuroSense CEO Alon

Tone
Positive 82/100
Event
Market update
Published
06 Jul 2026 13:10
Source
PR Newswire
TradingView Direct company coverage

Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN

This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating no current trades at the time of publication. The conte

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 11:10
Source
TradingView
TradingView Direct company coverage

NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings

This page provides access to NeuroSense Therapeutics Ltd.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. The documents detail the company's financial performance, operational updates, and progress of its drug PrimeC, particularly its effectiveness i

Tone
Positive 65/100
Event
Market update
Published
03 Jul 2026 23:10
Source
TradingView
Longevity.Technology Direct company coverage

NeuroSense bolsters case for multi-target Alzheimer’s strategy

NeuroSense Therapeutics has reported positive biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer’s disease, suggesting the therapy may be acting on shared neurodegeneration mechanisms across different diseases like ALS and Alzheimer's. The company's multi-targ

Tone
Positive 81/100
Event
Market update
Published
03 Jul 2026 16:04
Source
Longevity.Technology
PR Newswire Direct company coverage

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC for ALS successfully met its primary efficacy endpoint by demonstrating a statistically significant reduction in TDP-43 levels, a key pathological hallmark of ALS. This marks the first randomized, double

Tone
Positive 95/100
Event
Market update
Published
29 Jun 2026 13:13
Source
PR Newswire
Stock Titan Direct company coverage

NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3

NeuroSense Therapeutics announced its Phase 2b trial of PrimeC for ALS successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43, a key pathological hallmark of the disease. This reduction deepened and remained significant over

Tone
Positive 81/100
Event
Market update
Published
29 Jun 2026 13:13
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW

This article provides a specific financial metric, the "Price to sales forward," for NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW). It appears to be a stub or a data point from a financial platform, showing no additional details or commentary beyond the metric itself. The content p

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:40
Source
TradingView
PR Newswire Direct company coverage

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NeuroSense Therapeutics announced positive biomarker findings from its Phase 2 RoAD study of PrimeC in Alzheimer's disease (AD). The study, though small, showed PrimeC was associated with changes in key AD hallmark proteins like tau and amyloid-beta, as well as other neurodegener

Tone
Positive 73/100
Event
Market update
Published
27 Jun 2026 07:10
Source
PR Newswire
BioSpectrum Asia Direct company coverage

NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease

NeuroSense Therapeutics has announced promising biomarker findings from its Phase 2 RoAD study for PrimeC in Alzheimer’s disease. The small, exploratory study involving eight participants showed changes across multiple neurodegenerative disease pathways, supporting PrimeC's multi

Tone
Positive 75/100
Event
Market update
Published
26 Jun 2026 05:39
Source
BioSpectrum Asia
TradingView Direct company coverage

Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN)

This article provides an overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) stock performance, financial actuals, and analyst estimates. It details the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along wit

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 01:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW

This article provides financial information for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW), specifically its price-to-earnings forward ratio. The content appears to be a stub or a section of a larger financial data display from TradingView, indicating that the value and change

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 21:11
Source
TradingView
TradingView Direct company coverage

NRSN Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for NeuroSense Therapeutics Ltd. (NRSN) stock for 2027. It includes analyst ratings, earnings estimates, historical price performance, and answers frequently asked questions about the company's financials, market capitalization, e

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 19:11
Source
TradingView
TradingView Direct company coverage

Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z

This article focuses on the number of shareholders for Neurosense Therapeutics Ltd. (FWB:H1Z) on the Frankfurt Stock Exchange. It provides a placeholder for data regarding shareholder numbers, changes, and percentage changes over a specified period. The content is primarily a dat

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 15:11
Source
TradingView
Simply Wall Street Direct company coverage

NeuroSense Therapeutics (Nasdaq:NRSN) - Stock Analysis

NeuroSense Therapeutics (Nasdaq:NRSN) is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease using its lead drug candidate, PrimeC. The company has reported positive biomarker and long-term survi

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 13:40
Source
Simply Wall Street
Stock Titan Direct company coverage

NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s

NeuroSense Therapeutics (NRSN) announced positive early biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer’s disease. The study, involving eight patients with 12-month follow-up data from three, showed changes in key Alzheimer’s biomarkers and

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:11
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW

The article displays the enterprise value to EBITDA forward for NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW). It appears to be an unpopulated data point or a financial metric overview from TradingView, indicating no current trades or specific values for this financial ratio.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 09:10
Source
TradingView
Stock Titan Direct company coverage

ALS community event puts NeuroSense’s PrimeC data in focus June 24

NeuroSense Therapeutics announced that EverythingALS will host an online event on June 24, 2026, at 7 pm ET, focusing on emerging data for PrimeC in ALS treatment. The session will feature Professor Jeffrey Rosenfeld and NeuroSense CEO Alon Ben-Noon, aiming to inform ALS patients

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 09:00
Source
Stock Titan
TradingView Direct company coverage

NRSN Q1'26 Earnings: EPS estimate is (0.08) USD

NeuroSense Therapeutics Ltd. (NRSN) is expected to announce its Q1'26 earnings on June 22nd. The revenue estimate for the quarter is $514.10 thousand, with an anticipated EPS of ($0.08) USD. The article provides a table detailing past and estimated revenue and EPS figures.

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 10:40
Source
TradingView
TradingKey Direct company coverage

Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Neurosense Therapeutics Ltd (NRSN)'s dividend and stock split history. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split data. The current stock price and market capitalization a

Tone
Neutral 50/100
Event
Capital return
Published
19 Jun 2026 03:39
Source
TradingKey